BiotechTubeBiotechTube
Home/Outlook Therapeutics/Barry Cantrell
BC

Barry Cantrell

Author/Website Contact

Outlook Therapeutics

Therapeutic Areas

OphthalmologyRetinal Diseases

Outlook Therapeutics Pipeline

DrugIndicationPhase
ONS-5010 / LYTENAVA™ (bevacizumab-vikg)Wet Age-Related Macular Degeneration (wet AMD)Approved